Real-World Experience of Adalimumab in the Treatment of Hidradenitis Suppurativa

Published: 7 December 2020| Version 1 | DOI: 10.17632/pfz95dbvgm.1
Contributors:
,
,
,
,

Description

Supplemental Data on Reasons for Adalimumab Treatment Discontinuation and Secondary Treatment Initiated After Adalimumab Treatment Failure

Files

Institutions

University of Pittsburgh Medical Center

Categories

Hidradenitis Suppurativa

Licence